ATE444082T1 - Funktion eines haptoglobin-hämoglobin-rezeptors und anwendungszwecke dafür - Google Patents

Funktion eines haptoglobin-hämoglobin-rezeptors und anwendungszwecke dafür

Info

Publication number
ATE444082T1
ATE444082T1 AT01978210T AT01978210T ATE444082T1 AT E444082 T1 ATE444082 T1 AT E444082T1 AT 01978210 T AT01978210 T AT 01978210T AT 01978210 T AT01978210 T AT 01978210T AT E444082 T1 ATE444082 T1 AT E444082T1
Authority
AT
Austria
Prior art keywords
haptoglobin
function
receptor
hemoglobin receptor
complex
Prior art date
Application number
AT01978210T
Other languages
English (en)
Inventor
Soren Moestrup
Holger Moller
Original Assignee
Cytoguide Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytoguide Aps filed Critical Cytoguide Aps
Application granted granted Critical
Publication of ATE444082T1 publication Critical patent/ATE444082T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721Haemoglobin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445Haemoglobin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596Molecules with a "CD"-designation not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795Porphyrin- or corrin-ring-containing peptides
    • C07K14/805Haemoglobins; Myoglobins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01978210T 2000-10-16 2001-10-12 Funktion eines haptoglobin-hämoglobin-rezeptors und anwendungszwecke dafür ATE444082T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200001543 2000-10-16
DKPA200100039 2001-01-11
US27012001P 2001-02-22 2001-02-22
PCT/DK2001/000671 WO2002032941A2 (en) 2000-10-16 2001-10-12 The function of a haptoglobin-haemoglobin receptor and the uses thereof

Publications (1)

Publication Number Publication Date
ATE444082T1 true ATE444082T1 (de) 2009-10-15

Family

ID=27222446

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01978210T ATE444082T1 (de) 2000-10-16 2001-10-12 Funktion eines haptoglobin-hämoglobin-rezeptors und anwendungszwecke dafür

Country Status (10)

Country Link
US (3) US20020155995A1 (de)
EP (1) EP1328297B1 (de)
AT (1) ATE444082T1 (de)
AU (1) AU2002210383A1 (de)
CY (1) CY1110579T1 (de)
DE (1) DE60140069D1 (de)
DK (1) DK1328297T3 (de)
ES (1) ES2334103T3 (de)
PT (1) PT1328297E (de)
WO (1) WO2002032941A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002210383A1 (en) 2000-10-16 2002-04-29 Proteopharma Aps The function of a haptoglobin-haemoglobin receptor and the uses thereof
NZ528832A (en) 2001-03-26 2008-08-29 Hemosol Lp Blood cell production via activation of the hemoglobin scavenger receptor
AU2003243058A1 (en) * 2002-05-27 2003-12-12 Bioceros B.V. Methods for using the cd163 pathway for modulating an immune response
EP1367393A1 (de) * 2002-05-27 2003-12-03 MacroZyme B.V. Verfahren zur Verwendung des CD 163 Wegs zur Modulation einer Immunantwort
GB0423196D0 (en) * 2004-10-19 2004-11-24 Nat Blood Authority Method
WO2008019186A2 (en) * 2006-05-26 2008-02-14 Temple University - Of The Commonwealth System Of Higher Education Blood monocyte cd163 expression as a biomarker in hiv-1 infection and neuroaids
US20080293623A1 (en) * 2007-04-30 2008-11-27 Nhs Blood And Transplant Enriched haptoglobin polymers for the treatment of disease
GB0917044D0 (en) * 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
GB0917054D0 (en) * 2009-09-29 2009-11-11 Cytoguide As Agents, uses and methods
EP2488863A2 (de) 2009-10-12 2012-08-22 Aarhus Universitet Prognoseverfahren
GB201122325D0 (en) 2011-12-23 2012-02-01 Cytoguide As Novel formulations
KR20250099256A (ko) 2018-01-18 2025-07-01 프레드 허친슨 캔서 센터 세포 활성화 상태를 조절함으로써 생체내 면역 세포의 염증 상태의 변경
CN110256571A (zh) * 2018-11-30 2019-09-20 莱尔芙高新技术(上海)有限公司 重组人白蛋白-血红蛋白β亚基融合蛋白
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
EP3715374A1 (de) 2019-03-23 2020-09-30 Ablevia biotech GmbH Verbindung zur sequestrierung von unerwünschten antikörpern in einem patienten
EP3972646A4 (de) * 2019-05-20 2023-06-14 Ohio State Innovation Foundation Apohämoglobin-haptoglobin-komplexe und verfahren zur verwendung davon
CN114423787B (zh) 2019-07-19 2025-01-24 昂科里斯庞斯公司 免疫调节性抗体及其使用方法
KR102254246B1 (ko) * 2020-03-23 2021-05-20 큐벳 주식회사 항-cd163 항체 또는 이의 항원 결합 단편을 인코딩하는 핵산 분자 및 이를 포함하는 아데노바이러스 벡터, 및 이의 아프리카 돼지열병의 예방 또는 치료용도
EP4217402A1 (de) 2020-09-23 2023-08-02 Ablevia biotech GmbH Verbindung zur prävention oder behandlung von autoantikörpervermittelten erkrankungen
CA3192744A1 (en) 2020-09-23 2022-03-31 Oskar SMRZKA Compound for the sequestration of undesirable anti-peg antibodies in a patient
CN116669755A (zh) 2020-09-23 2023-08-29 艾柏力维亚生技有限公司 用于增加因子viii替代疗法的效力的化合物
CN116547008A (zh) 2020-09-23 2023-08-04 艾柏力维亚生技有限公司 用于增加病毒载体的效力的化合物
EP4216990A1 (de) 2020-09-23 2023-08-02 Ablevia biotech GmbH Verbindung zur sequestrierung von unerwünschten antikörpern in einem patienten
US20230381328A1 (en) 2020-09-24 2023-11-30 Ablevia Biotech Gmbh Compound for the prevention or treatment of myasthenia gravis
ES3064029T3 (en) * 2021-01-05 2026-04-22 Public Univ Corp Yokohama City Univ Biomarker for determining fertility, and determining method using same
US20250213707A1 (en) 2022-03-24 2025-07-03 Ablevia Biotech Gmbh Compound for increasing efficacy of oncolytic viruses
EP4655324A1 (de) 2023-01-27 2025-12-03 Vib Vzw Cd163-bindende konjugate

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4177A (en) * 1845-09-02 Phineas bennet
US41177A (en) * 1864-01-05 Tiios
US4061735A (en) * 1973-11-15 1977-12-06 The Green Cross Corporation Haptoglobin in aqueous solution and process for preparing the same
JPS52128205A (en) * 1976-04-16 1977-10-27 Green Cross Corp:The Prophylactic and therapeutic drugs for cerebro-vascular contraction
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5155020A (en) 1989-03-08 1992-10-13 Health Research Inc. Recombinant poxvirus host range selection system
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
KR0162259B1 (ko) * 1989-12-05 1998-12-01 아미 펙터 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
US5204243A (en) 1990-02-14 1993-04-20 Health Research Incorporated Recombinant poxvirus internal cores
US5252348A (en) 1990-10-19 1993-10-12 Univ. Of Florida Research Foundation, Inc. Artificial viral envelopes
JPH11505505A (ja) 1994-06-27 1999-05-21 ザ・ジョンズ・ホプキンス・ユニバーシティー ターゲッティングされた遺伝子輸送システム
US5691197A (en) 1995-02-21 1997-11-25 Tryggvason; Karl Isolated DNA sequence for a novel macrophage receptor with a collagenous domain
EP0871755A1 (de) 1995-03-23 1998-10-21 Cantab Pharmaceuticals Research Limited Vektoren zur verabreichung von genen
US6204054B1 (en) * 1995-09-21 2001-03-20 Andaris Limited Transcytosis vehicles and enchancers for drug delivery
US6479258B1 (en) * 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US5972899A (en) 1996-01-25 1999-10-26 New York University Apoptosis induced by Shigella IpaB
JP2000514440A (ja) 1996-07-09 2000-10-31 ザ ジョーンズ ホプキンス ユニバーシティー 遺伝子輸送システム
US6605699B1 (en) * 1997-01-21 2003-08-12 Human Genome Sciences, Inc. Galectin-11 polypeptides
US6046314A (en) 1997-03-06 2000-04-04 Bristol-Myers Squibb Co. Spα: a novel scavenger receptor cysteine-rich domain-containing polypeptide, and monoclonal antibodies thereto
US5962667A (en) 1997-11-03 1999-10-05 Virginia Commonwealth University Pharmaco-gene delivery in human breast cancer cells
CA2236344A1 (en) * 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
CA2404964A1 (en) * 2000-03-28 2001-10-04 Paul M. Guyre Methods for detecting inflammation and inflammatory conditions
AU2002210383A1 (en) 2000-10-16 2002-04-29 Proteopharma Aps The function of a haptoglobin-haemoglobin receptor and the uses thereof
GB0917044D0 (en) * 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods

Also Published As

Publication number Publication date
DE60140069D1 (de) 2009-11-12
WO2002032941A8 (en) 2004-04-29
US20050063951A1 (en) 2005-03-24
WO2002032941A3 (en) 2002-07-25
ES2334103T3 (es) 2010-03-05
EP1328297B1 (de) 2009-09-30
PT1328297E (pt) 2010-01-04
US20020155995A1 (en) 2002-10-24
AU2002210383A1 (en) 2002-04-29
CY1110579T1 (el) 2015-04-29
DK1328297T3 (da) 2010-02-01
US20080242843A1 (en) 2008-10-02
EP1328297A2 (de) 2003-07-23
WO2002032941A2 (en) 2002-04-25
US9476890B2 (en) 2016-10-25

Similar Documents

Publication Publication Date Title
ATE444082T1 (de) Funktion eines haptoglobin-hämoglobin-rezeptors und anwendungszwecke dafür
TR200101814T2 (tr) Sulu reaktif dolgu bileşimleri (II)
WO2006040129A3 (de) Ubiquittin oder gamma-kristallin-konjugate zur verwendung in therapie, diagnose und chromatographie
ATE455127T1 (de) Humane anti-humane cd3-bindungsmoleküle
BR0112631A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, pacote, métodos de reduzir a condutáncia de cálcio de um receptor de capsaicina e de tratar um mamìfero e uso de um composto
EP1436003A4 (de) Taci-immunoglobulin-fusionsproteine
WO2005077981A3 (en) Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
NO20062087L (no) Bispesifikt antistoff som substituerer for funksjonelle proteiner
DK1124568T3 (da) Polyspecifikke bindingsmolekyler og anvendelser deraf
BRPI0415448A8 (pt) método de alvejar populações de célula específica empregando-se conjugados de maytansinoid de agente de ligação celular ligados por meio de um ligante não-clivável, os referidos conjugados, e métodos de preparação dos referidos conjugados
ES2293973T3 (es) Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos.
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
CR10878A (es) Anticuerpos para cd40 (divisional de exp. 7343)
BRPI0511008A (pt) agentes de ligação de il-13
DE60045847D1 (de) Rezeptorbindende konjugate
DK1216707T3 (da) Fremgangsmåde til screening af ligandmolekyler, der specifikt binder til NEP-bindingsstederne for QHNPR-pentapeptidet
WO2008013954A3 (en) Tyrosine phosphorylation sites
NO20021686D0 (no) Fremgangsmåter for fremstilling av målemolekyler i et transgent dyr og rensing av målmolekylet
WO2008054597A3 (en) Tyrosine phosphorylation sites
BRPI0513149A (pt) uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituìdas no tratamento de náuseas e vÈmito
WO2008013934A3 (en) Tyrosine phosphorylation sites
EA200702193A1 (ru) Гликозилирование белков
NO20074805L (no) Fremgangsmate for a identifisere PDE11-modulatorer
YU17503A (sh) Receptor oblasti (ii) edb-fibronektina
BRPI0508084A (pt) método para o tratamento de um distúrbio neurológico, e, uso de meridamicina ou um sal do mesmo

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1328297

Country of ref document: EP